1934-71-0

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenylcyclohexylamine Hydrochloride is used as a chemical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its role in the industry is crucial for developing new medications and enhancing the efficacy of existing ones.
Used in Research Chemicals:
As a research chemical, 1-Phenylcyclohexylamine Hydrochloride is utilized in scientific studies and experiments to explore its properties and potential applications, contributing to the advancement of knowledge in chemistry and related fields.
Used in Agrochemicals Industry:
Although not explicitly mentioned in the provided materials, given its potential applications in other industries, 1-Phenylcyclohexylamine Hydrochloride could be used as a component in the development of agrochemicals, possibly for the synthesis of pesticides or other agricultural products, leveraging its chemical properties to improve crop protection or yield.
Used in Materials Science:
Similarly, in materials science, 1-Phenylcyclohexylamine Hydrochloride may have potential uses in the development of new materials or the modification of existing ones, taking advantage of its unique characteristics to create innovative solutions in various material applications.

InChI:InChI=1/C12H17N.ClH/c13-12(9-5-2-6-10-12)11-7-3-1-4-8-11;/h1,3-4,7-8H,2,5-6,9-10,13H2;1H

Upstream product

• 1934-58-3 Benzyl-(1-phenyl-cyclohexyl)-amine; hydrochloride 
• 100-47-0 benzonitrile 
• 23708-48-7 pentamethylenebis(magnesium bromide) 
• 2201-24-3 1-phenylcyclohexylamine 
• 1589-60-2 1-phenylcyclohexanol 
• 66021-71-4 1-(1-azidocyclohexyl)benzene 
• 2890-60-0 1-phenylcyclohexane-1-carboxamide 

Downstream Products

• 93185-14-9 5-valeraldehyde ethylene acetal 
• 5769-29-9 N-<4-Chlor-benzolsulfonyl>-N'-<1-phenyl-cyclohexyl>-harnstoff 

Relevant academic research and scientific papers

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

Syntheses and N-methyl-D-aspartate receptor antagonist pharmacology of fluorinated arylcycloheptylamines

Selective uncompetitive antagonists of the phencyclidine (PCP) binding site of the N-methyl-D-aspartate receptor (NMDAR) are known to have therapeutic potential as anticonvulsants and neuroprotective agents. Several fluorinated molecules with each containing a cycloheptane ring were designed to probe the PCP pharmacophore and test the influence of fluorine substitution on NMDAR binding and in vivo efficacy. Syntheses and analyses of six novel compounds, 1-(4-fluorophenyl)cycloheptanamine (3), 1-(1-(4-fluorophenyl)cycloheptyl)piperidine (4), 1-(1-(4-fluorophenyl)cycloheptyl) pyrrolidine (5), 1-(3-fluorophenyl)cycloheptanamine (6), 1-(1-(3-fluorophenyl)cycloheptyl)piperidine (7), 1-(1-(3-fluorophenyl)cycloheptyl)pyrrolidine (8) and several related reference arylcyloalkylamines are described. Receptor binding was performed at the PCP site of NMDAR for each compound using [3H]-(+)-MK-801 displacement. Unexpectedly, the 3-fluoro-primary amine 6 had the greatest affinity of the series and these binding results support a different structure activity relationship (SAR) profile for arylcycloheptylamines when compared to arylcyclohexylamines like PCP. Five of the novel compounds have affinity (Ki) in the hundred nM (10-7) range. In addition, compounds 3, 5, 6, 7 and 8 were evaluated and found to exhibit neuroprotective effects from NMDA induced toxicity in vitro and compounds 6, 7 and 8 exhibited anticonvulsant activities in rats. An ED50 of 13.84 mg/kg was found for compound 6 in rat maximal electroshock (MES) test with a protective index (PI) of 3.66 against ataxia. These results support further investigation of the arylcycloheptylamine class.

1-Substituted cyclopentylamines from nitriles and tetramethylenebismagnesium dibromide in the presence of Ti(OiPr)4

Various 1-substituted cyclopentylamines (25 examples, 1089 % yield) have been prepared according to a one-pot procedure by the addition of tetramethylenebismagnesium. di- bromide in the presence of Ti(OiPr)4 to aliphatic, aromatic and heteroaromatic nitriles, respectively.

Metabolism of phencyclidine. The role of the carbinolamine intermediate in the formation of lactam and amino acid metabolites of nitrogen heterocycles

The transformation of phencyclidine in a mouse liver microsome preparation to several oxidative metabolites was studied. With use of GLC and HPLC methods with internal standards, phencyclidine and six metabolites were quantitated and the amino acid, resulting from the α-oxidation of the piperidine ring, was produced in 10-50 times greater amounts than the other metabolites. While most piperidines and pyrrolidines produce an amino acid and a corresponding lactam, it was found that phencyclidine was not converted to the lactam.